The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Achillion Pharmaceuticals, Inc | COM | 00448Q201 | 13,737 | 1,679,340 | SH | DFND | 3 | 1,679,340 | 0 | 0 | |
| Alexion Pharmaceuticals, Inc. | COM | 015351109 | 71,774 | 778,126 | SH | DFND | 2 | 778,126 | 0 | 0 | |
| Alnylam Pharmaceuticals, Inc. | COM | 02043Q107 | 14,099 | 454,800 | SH | DFND | 3 | 454,800 | 0 | 0 | |
| Ariad Pharmaceuticals, Inc | COM | 04033A100 | 54,488 | 3,115,371 | SH | DFND | 3 | 3,115,371 | 0 | 0 | |
| Biomarin Pharmaceutical Inc | COM | 09061G101 | 9,923 | 178,028 | SH | DFND | 2 | 178,028 | 0 | 0 | |
| Celgene Corporation | COM | 151020104 | 251,529 | 2,150,186 | SH | DFND | 2 | 2,150,186 | 0 | 0 | |
| Dendreon Corporation | COM | 24823Q107 | 4,181 | 1,014,800 | SH | DFND | 2 | 1,014,800 | 0 | 0 | |
| Endocyte, Inc. | COM | 29269A102 | 30,716 | 2,339,345 | SH | DFND | 3 | 2,339,345 | 0 | 0 | |
| Gilead Sciences, Inc. | COM | 375558103 | 189,699 | 3,700,000 | SH | DFND | 1 | 3,700,000 | 0 | 0 | |
| Halozyme Therapeutics, Inc. | COM | 40637H109 | 44,890 | 5,646,519 | SH | DFND | 3 | 5,646,519 | 0 | 0 | |
| Idenix Pharmaceuticals, Inc. | COM | 45166R204 | 4,513 | 1,250,000 | SH | DFND | 3 | 1,250,000 | 0 | 0 | |
| Immunogen, Inc. | COM | 45253H101 | 54,118 | 3,262,094 | SH | DFND | 3 | 3,262,094 | 0 | 0 | |
| Incyte Corporation | COM | 45337C102 | 117,857 | 5,357,149 | SH | DFND | 3 | 5,357,149 | 0 | 0 | |
| Infinity Pharmaceuticals, Inc. | COM | 45665G303 | 17,646 | 1,089,828 | SH | DFND | 3 | 1,089,828 | 0 | 0 | |
| Isis Pharmaceuticals, Inc. | COM | 464330109 | 208,758 | 7,769,172 | SH | DFND | 3 | 7,769,172 | 0 | 0 | |
| Medivation, Inc. | COM | 58501N101 | 71,326 | 1,449,706 | SH | DFND | 3 | 1,449,706 | 0 | 0 | |
| Onyx Pharmaceuticals, Inc. | COM | 683399109 | 47,447 | 546,500 | SH | DFND | 2 | 546,500 | 0 | 0 | |
| Optimer Pharmaceuticals, Inc. | COM | 68401H104 | 20,934 | 1,446,700 | SH | DFND | 3 | 1,446,700 | 0 | 0 | |
| Synageva BioPharma Corp. | COM | 87159A103 | 2,248 | 53,549 | SH | DFND | 3 | 53,549 | 0 | 0 | |
| The Medicines Company | COM | 584688105 | 9,320 | 302,993 | SH | DFND | 2 | 302,993 | 0 | 0 | |
| Theravance, Inc. | COM | 88338T104 | 34,224 | 888,244 | SH | DFND | 3 | 888,244 | 0 | 0 | |
| Trius Therapeutics, Inc. | COM | 89685K100 | 2,268 | 280,000 | SH | DFND | 3 | 280,000 | 0 | 0 | |
| Vertex Pharmaceuticals Incorporated | COM | 92532F100 | 112,440 | 1,404,445 | SH | DFND | 3 | 1,404,445 | 0 | 0 | |